
Scholar Rock Holding Corp
SRRKHealthcare|Biotechnology|USA
$56.75
-1.26 (-2.17%)
Tangible Book
$2.32
Earnings Power
$2.96
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
6.86,
152.06,
366.85,
544.66,
811.42
],
"ebit_estimate": [
-424.07,
-330.46,
-172.87,
-32.66,
216.03
],
"ebitda_estimate": [
-413.83,
-308.44,
-127.82,
null,
null
],
"net_income_estimate": [
-404.42,
-332.95,
-181.88,
44.11,
208.37
],
"per_share_eps_estimate": [
-3.22,
-2.49,
-1.37,
0.18,
1.54
],
"eps_nri_estimate": [
-3.21,
-2.51,
-1.32,
0.32,
1.51
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
2.06,
2.12,
1.71,
null,
null
],
"pretax_income_estimate": [
-402.41,
-338.08,
-181.08,
-20.18,
215.53
],
"operating_cash_flow_per_share_estimate": [
-2.87,
-1.72,
-0.78,
null,
null
],
"roa_estimate": [
-58.1,
-88.1,
-69.6,
null,
null
],
"roe_estimate": [
-222.98,
-706.08,
31.09,
null,
null
],
"gross_margin_estimate": [
86.6,
88,
88.2,
89,
89.67
],
"operating_cash_flow_estimate": [
-365.29,
-219.34,
-98.64,
null,
null
],
"pettm_estimate": [
0,
0,
0,
315.28,
36.85
],
"long_term_growth_rate_mean": 25.86,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 24.98,
"future_eps_nri_estimate_growth": 25.86,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 23.27,
"future_ebitda_estimate_growth": 30.14,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 21.25,
"future_pretax_income_estimate_growth": 21.19,
"future_book_value_per_share_estimate_growth": -7.9,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": -3.54,
"future_operating_cash_flow_per_share_estimate_growth": 34.03
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
null,
1.87,
5.62,
17.16,
26.07,
59.89,
83.5,
84.62
],
"ebit_estimate": [
-105.93,
-110.85,
-97.1,
-113.85,
-102.48,
-94.17,
-80.1,
null
],
"ebitda_estimate": [
-106.94,
-113.94,
-65.35,
null,
null,
null,
null,
null
],
"net_income_estimate": [
-106.67,
-111.88,
-108.14,
-119.72,
-108.35,
-100.05,
-85.97,
null
],
"per_share_eps_estimate": [
-0.85,
-0.85,
-0.78,
-0.65,
-0.61,
-0.45,
-0.43,
null
],
"eps_nri_estimate": [
-0.84,
-0.85,
-0.78,
-0.72,
-0.67,
-0.54,
-0.49,
-0.4
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-106.45,
-111.65,
-84.39,
-119.72,
-108.35,
-100.05,
-85.97,
null
],
"operating_cash_flow_per_share_estimate": [
-0.84,
-0.86,
-0.86,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
88,
87.67,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
-106.91,
-109.46,
-109.46,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null,
null
],
"long_term_growth_rate_mean": 25.86,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 24.98,
"future_eps_nri_estimate_growth": 25.86,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 23.27,
"future_ebitda_estimate_growth": 30.14,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 21.25,
"future_pretax_income_estimate_growth": 21.19,
"future_book_value_per_share_estimate_growth": -7.9,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": -3.54,
"future_operating_cash_flow_per_share_estimate_growth": 34.03
}